Study Type: POEM Purpose: For patients with GI bleed from aspirin, do we add a proton pump inhibitor or switch to clopidogrel? Study Duration: 1 year Trial Design: Double-blinded, placebo-controlled, randomized, intention-to-treat, one hospital site in Hong Kong. Screened patients who presented on aspirin with a upper GI bleed , endoscopy performed, biopsy performed at 3 sites. Those h.pylori positive were treated with antibiotics and proton pump inhibitors (PPI). After 8 weeks, repeat endoscopy was performed, those healed were randomized. Drug: Clopidogrel 75 mg daily + esomeprazole placebo versus ASA 80 mg daily + esomeprazole 20 mg twice a day Patients: 320 patients out of 492 screened, mean age 72 years, ~67% male, There were more smokers in the clopidogrel group (13% vs 8.2%), more alcohol assumption (8.1% vs 5%); Most ulcers were gastric oriented, however, more in the ASA/esomeprazole had duodenal ulcers (8% increase), ~50% in each group had a cardiac history Inclusion: patients admitted to the hospital with GI bleed and user of aspirin, confirmed bleed via endoscopy, negative h.pylori, successfully treat h.pylori before study Exclusion: NSAID use, anticoagulants, other anti platelets, steroids, history of gastric surgery, allergy to ASA or clopidogrel, erosive esophagitis, gastric-outlet obstruction, renal failure requiring dialysis, terminal illness or cancer, Outcome Events: Primary: recurrent ulcer bleed determined by hematemesis or melena, ulcers or bleeding erosions on endoscopy, decrease Hb at least 2 gm. Secondary: lower GI bleeds
1.
Are Extragastrointestinal bleeding -3 patients in clopidogrel group (2 intracranial bleeds, one hematuria) and none in the ASA/esomeprazole No real difference in recurrent ischemic events.
3.
Will the results help me? * The author's raise concern about the GI safety of clopidogrel mainly due to the fact that those who had recurrent bleeds were NOT h.pylori positive * They screened for NSAID use (national pharmacy computer database). Only 2 patients with recurrent bleeds used NSAIDs. * 71% of the recurrent bleeds were in the same location. There is a theory that clopidogrel may inhibit platelet-derived growth factors and retard healing. * The authors did not mention the few differences noted in the study patients. See above. Would patients in the clopidogrel group be more at risk to have a GI bleed? * Esomeprazole is dosed 20 mg twice a day. Maybe the main difference is the benefit of esomeprazole.
